Flora of China

SHAREHOLDER ALERT: Robbins LLP Announces that Akebia Therapeutics, Inc. (AKBA) is Being Sued for Misleading Keryx Biopharmaceuticals, Inc. (KERX) Shareholders Ahead of Merger

Retrieved on: 
Monday, July 26, 2021

Akebia is a biopharmaceutical company that develops and commercializes therapeutics for patients based on hypoxia-inducible factor ("HIF") technology.

Key Points: 
  • Akebia is a biopharmaceutical company that develops and commercializes therapeutics for patients based on hypoxia-inducible factor ("HIF") technology.
  • If you suffered a loss due to Akebia Therapeutics, Inc.'s misconduct, click here .
  • According to the complaint, the Registration Statement issued in connection with the December 2018 merger of Keryx with Akebia contained untrue statements of material fact.
  • If you owned shares of Keryx Biopharmaceuticals, Inc. and received shares of Akebia Therapeutics, Inc. (AKBA) in the December 2018 merger, contact us to discuss your options.

Akebia Therapeutics to Report Second Quarter 2021 Financial Results and Discuss Recent Business Highlights

Retrieved on: 
Monday, July 26, 2021

CAMBRIDGE, Mass., July 26, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA),a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the second quarter ended June 30, 2021, on Thursday, August 5, 2021 before the opening of the financial markets.

Key Points: 
  • CAMBRIDGE, Mass., July 26, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA),a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the second quarter ended June 30, 2021, on Thursday, August 5, 2021 before the opening of the financial markets.
  • Akebia will host a conference call at 9:00 a.m. Eastern Time on Thursday, August 5, to discuss its second quarter financial results and recent business highlights.
  • A replay of the conference call will be available two hours after the completion of the call throughAugust 11, 2021.
  • Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease.

Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat

Retrieved on: 
Friday, June 4, 2021

Under the terms of the agreement, Akebia has obtained an exclusive license to research, develop and commercialize praliciguat globally and will be solely responsible for these activities going forward.

Key Points: 
  • Under the terms of the agreement, Akebia has obtained an exclusive license to research, develop and commercialize praliciguat globally and will be solely responsible for these activities going forward.
  • Cyclerion is eligible to receive up to $225M in pre-commercial milestones, including up to $15M in the first 18 months.
  • We are very pleased to license praliciguat to Akebia, whose demonstrated leadership in kidney disease and extensive R&D and commercialization capabilities make it an ideal partner for the future development of praliciguat.
  • Cyclerion Therapeutics is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function.

Akebia Therapeutics to Report First Quarter 2021 Financial Results and Discuss Recent Business Highlights

Retrieved on: 
Wednesday, April 28, 2021

b"CAMBRIDGE, Mass., April 28, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA),a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the first quarter ended March 31, 2021, on Monday, May 10, 2021 before the opening of the financial markets.\nAkebia will host a conference call at 9:00 a.m. Eastern Time on Monday, May 10, to discuss its first quarter financial results and recent business highlights.

Key Points: 
  • b"CAMBRIDGE, Mass., April 28, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA),a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the first quarter ended March 31, 2021, on Monday, May 10, 2021 before the opening of the financial markets.\nAkebia will host a conference call at 9:00 a.m. Eastern Time on Monday, May 10, to discuss its first quarter financial results and recent business highlights.
  • To listen to the conference call, please dial (877) 458-0977 (domestic) or (484) 653-6724 (international) using conference ID number6250159.
  • To access the replay, dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and reference conference ID number6250159.
  • For more information, please visit our website at www.akebia.com , which does not form a part of this release.\n"

Heze, China: A Flower That Vitalizes A City

Retrieved on: 
Wednesday, April 14, 2021

The peony heritage of Heze will once again amaze visitors from all over the world.

Key Points: 
  • The peony heritage of Heze will once again amaze visitors from all over the world.
  • Its peony industry has developed in a multi-faceted way, producing a range of peony-based merchandise such as ornamentals, medicines and health products.
  • Additionally, peony-themed creative and cultural output, such as peony flowers, peony print silk and traditional Chinese peony flower paper-cutting, is also flourishing.\nThere are nine ornamental peony gardens in Heze, the more notable including the Caozhou Peony Garden, the Baihua Peony Garden and the Chinese Peony Garden.
  • The peony sector currently provides more than 100,000 jobs in Heze, covering the gamut from peony cultivation to processing and sales.

Akebia Therapeutics Appoints LeAnne M. Zumwalt, Dialysis Industry Leader, to Board of Directors

Retrieved on: 
Thursday, February 18, 2021

"We're honored to have LeAnne Zumwalt join the Akebia Board of Directors," said John P. Butler, President and Chief Executive Officer of Akebia Therapeutics.

Key Points: 
  • "We're honored to have LeAnne Zumwalt join the Akebia Board of Directors," said John P. Butler, President and Chief Executive Officer of Akebia Therapeutics.
  • "I'm excited to join Akebia during what I believe is a pivotal time for the Company and the kidney community," said Ms. Zumwalt.
  • Akebia also announced that Maxine Gowen, Ph.D., will resign from the Board of Directors of Akebia, effective June 6, 2021.
  • Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease.

Farlong Pharmaceutical Encourages Cardiovascular Awareness Throughout American Heart Month

Retrieved on: 
Tuesday, February 16, 2021

WALNUT, Calif., Feb. 16, 2021 /PRNewswire-PRWeb/ -- Farlong Pharmaceutical , a vertically integrated, plant-based ingredient and supplement company, is recognizing American Heart month this February by highlighting Traditional Chinese Medicine such as Ginseng Plus Panax Notoginseng , Heart Advanced Support and Danshen root .

Key Points: 
  • WALNUT, Calif., Feb. 16, 2021 /PRNewswire-PRWeb/ -- Farlong Pharmaceutical , a vertically integrated, plant-based ingredient and supplement company, is recognizing American Heart month this February by highlighting Traditional Chinese Medicine such as Ginseng Plus Panax Notoginseng , Heart Advanced Support and Danshen root .
  • Notoginseng root is traditionally used to help alleviate angina (chest pain) and heart attacks.
  • Danshen, the root of Salvia miltiorrhiza, is used to support ailments of the heart and blood vessels along with angina.
  • Since 1998, Farlong Pharmaceutical has combined ancient Oriental medicine and modern technology to create a line of natural and safe products that promote a healthy life.

Akebia Therapeutics to Report Fourth Quarter and Full-Year 2020 Financial Results and Discuss Recent Business Highlights

Retrieved on: 
Monday, February 8, 2021

Akebia will host a conference call at 9:00 a.m. Eastern Time on Thursday, February 25, 2021 to discuss its fourth quarter and full-year 2020 financial results and recent business highlights.

Key Points: 
  • Akebia will host a conference call at 9:00 a.m. Eastern Time on Thursday, February 25, 2021 to discuss its fourth quarter and full-year 2020 financial results and recent business highlights.
  • To listen to the conference call, please dial (877) 458-0977 (domestic) or (484) 653-6724 (international) using conference ID number 5455117.
  • The call will also be webcast live and can be accessed via the Investors section of the Company's website at http://ir.akebia.com .
  • Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease.

Clariant Lauded by Frost & Sullivan for Addressing the Growing Customer Demand for Natural Anti-aging Active Ingredients with its Product, Prenylium®

Retrieved on: 
Tuesday, December 15, 2020

A combination of factors such as sustainable ingredient sourcing and greater efficiency than traditional mulberry root extract has positioned Clariant ahead of its competitors.

Key Points: 
  • A combination of factors such as sustainable ingredient sourcing and greater efficiency than traditional mulberry root extract has positioned Clariant ahead of its competitors.
  • The Prenylium active ingredient is an extract of the Morus alba tree root, which has been used for centuries in traditional Chinese medicine.
  • Clariant's product delivers on customer expectations for younger-looking skin by adjusting matrisome components, including glycoproteins, collagen, and proteoglycans.
  • "Prenylium is developed in a highly sustainable, traceable, and natural environment, thus meeting the consumer demand for environment-friendly ingredients.

Clariant Lauded by Frost & Sullivan for Addressing the Growing Customer Demand for Natural Anti-aging Active Ingredients with its Product, Prenylium®

Retrieved on: 
Tuesday, December 15, 2020

A combination of factors such as sustainable ingredient sourcing and greater efficiency than traditional mulberry root extract has positioned Clariant ahead of its competitors.

Key Points: 
  • A combination of factors such as sustainable ingredient sourcing and greater efficiency than traditional mulberry root extract has positioned Clariant ahead of its competitors.
  • The Prenylium active ingredient is an extract of the Morus alba tree root, which has been used for centuries in traditional Chinese medicine.
  • Clariant's product delivers on customer expectations for younger-looking skin by adjusting matrisome components, including glycoproteins, collagen, and proteoglycans.
  • "Prenylium is developed in a highly sustainable, traceable, and natural environment, thus meeting the consumer demand for environment-friendly ingredients.